四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

已收盘 11-09 16:08:05

0.785

-0.015

-1.87%

最高0.820	最低0.785	成交量1,574万
今开0.800	昨收0.800	日振幅4.38%
总市值71.56亿	流通市值71.56亿	总股本91.16亿
成交额1,262万	换手率0.17%	流通股本91.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.785,"timestamp":1794211685003,"preClose":0.8,"halted":0,"volume":15740000,"delay":0,"changeRate":-0.018750000000000017,"floatShares":9116000000,"shares":9116000000,"eps":0.0197,"marketStatus":"已收盘","change":-0.015,"latestTime":"11-09 16:08:05","open":0.8,"high":0.82,"low":0.785,"amount":12622675,"amplitude":0.04375,"askPrice":0.79,"askSize":218000,"bidPrice":0.785,"bidSize":482000,"shortable":3,"etf":0,"ttmEps":0.038573,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":5,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":0.8,"dividendRate":0.014264,"openAndCloseTimeList":[[1794187800000,1794196800000],[1794200400000,1794211200000]],"volumeRatio":0.394957,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2681880484","title":"医美概念股局部走高 四环医药（00460）涨2.53% 机构指行业结构性机会持续存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2681880484","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681880484?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:05","pubTimestamp":1793930738,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股局部走高，截至发稿，四环医药（00460）涨2.53%，美丽田园医疗健康（02373）涨1.99%，时代天使（06699）涨2.00%，三生制药（01530）涨1.69%，康哲药业（00867）涨1.61%。消息面上，中信证券研究指，医美行业当前处于上游注册证快速增加的阶段，竞争较为激烈，但结构性机会持续存在：差异化新品红利仍存，营销获客、医学推广、产品组合、渠道运营等综合能力强的上游品牌有望在竞争中胜出。下游显著受益于产业链格局变化，能够夯实自身美誉度、降低获客成本以及提供综合解决方案、提升毛利率的下游品牌有望持续提升份额。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995397","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","SG9999015978.USD","BK1600","HK0000165453.HKD","BK1215","SG9999015952.SGD","00867","BK1100","BK1515","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999004220.SGD","01530","06699","02373","IE00BMCWC346.EUR","IE00BVYPNP33.GBP","IE00BYV24P56.USD","LU2488822045.USD","BK1583","BK1191","BK1593","IE00BGHQDM52.EUR","SG9999004311.SGD","BK1161","BK1587","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681090186","title":"【券商聚焦】国泰海通证券：美护板块估值及持仓均处底位，看好成长型标的修复弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2681090186","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681090186?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:06","pubTimestamp":1793840817,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国泰海通证券研究指，26Q3美护板块收入/归母/扣非同比+10%/-36%/-29%，细分板块中个护稳健，美妆高端好于大众，医美下游好于上游，当前板块估值及持仓均处底位，看好成长型标的修复弹性。该机构推荐：1）基本面强劲的高成长标的；2）估值较低的龙头标的；3）预期低位、后续边际有望改善的标的。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004311.SGD","01530","LU0502904849.HKD","161027","01830","BK1593","02196","BK1147","LU2242644610.SGD","601211","02373","BK0201","BK1564","BK1100","BK0188","BK1585","BK0276","BK0184","02138","02611","BK1587","06699","BK0012","BK1161","LU2488822045.USD","01696","BK1207","BK1215","BK1515","00460","BK1600","BK1583","BK1511","BK0028","HK0000165453.HKD","02145","LU0455707207.USD","BK0183","BK1191","02367","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144413150","title":"四环医药更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1144413150","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144413150?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:06","pubTimestamp":1793606764,"startTime":"0","endTime":"0","summary":"四环医药于2026年11月2日发布截至2026年10月31日的股份变动月报表。公告显示，公司本月未有任何新增股份发行或回购及注销活动，股本架构保持不变。本期末，公司法定股本维持为100,000,000,000股，每股面值港币0.01元，合计法定股本为港币1,000,000,000元。公司表示，目前已符合香港联交所上市规则要求，并确认遵守相关监管规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136422531","title":"四环医药（00460）披露安奈拉唑钠治疗反流性食管炎III期研究结果 于UEG Week 2026发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1136422531","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136422531?lang=zh_cn&edition=full","pubTime":"2026-10-21 21:00","pubTimestamp":1792587636,"startTime":"0","endTime":"0","summary":"2026年10月21日，四环医药控股集团有限公司公告称，其旗下非全资附属公司轩竹生物科技股份有限公司自主研发的国家1类创新药安奈拉唑钠肠溶片治疗反流性食管炎的III期注册临床研究数据，已在西班牙巴塞罗那举行的第34届欧洲消化疾病周以Late-Breaking Abstract口头报告形式进行展示。四环医药表示，此次自愿公告旨在向投资者披露集团业务最新进展，不构成对任何药物或治疗的宣传。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676340666","title":"四环医药（00460）两款产品相继于香港获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2676340666","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676340666?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:59","pubTimestamp":1792486780,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药（00460）公告公布，近期，集团旗下渼颜空间生物科技（吉林）有限公司（“渼颜空间”）自主研发及生产的注射用聚己内酯微球面部填充剂（“PCL”）、注射用透明质酸钠复合溶液(FL)（“动能素”），已相继于香港获批上市。此次获批的注射用聚己内酯微球面部填充剂获批规格包括0.5mL╱支、1.0mL╱支、2.0mL╱支；注射用透明质酸钠复合溶液获批规格包括0.5mL╱支、1.0mL╱支、1.5mL╱支、2.0mL╱支、2.5mL╱支、3.0mL╱支、5mL╱盒（内含2支2.5mL╱支规格产品）。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","BK1191","IPOS","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191968425","title":"四环医药（00460）两款自研医美注射产品获香港上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1191968425","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191968425?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:55","pubTimestamp":1792486542,"startTime":"0","endTime":"0","summary":"2026年10月20日，四环医药控股集团有限公司公告称，其旗下渼颜空间生物科技（吉林）有限公司自主研发并生产的两款医美注射产品——注射用聚己内酯微球面部填充剂及注射用透明质酸钠复合溶液（动能素）已相继获得中国香港特别行政区的上市批准。本次两款产品获香港注册，扩大了产品市场空间，并为集团深入拓展香港及辐射亚太地区奠定基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676666843","title":"四环医药(00460.HK)：渼颜空间自主研发的注射用聚己内酯微球面部填充剂、注射用透明质酸钠复合溶液在香港获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2676666843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676666843?lang=zh_cn&edition=full","pubTime":"2026-10-20 16:54","pubTimestamp":1792486454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00460","BK1191","BK1515","BK1593","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675961573","title":"四环医药抢先押注“全长三螺旋”，一场重组人III型胶原蛋白稀缺原料的卡位战","url":"https://stock-news.laohu8.com/highlight/detail?id=2675961573","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675961573?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:51","pubTimestamp":1791939099,"startTime":"0","endTime":"0","summary":"提前锁定了一张下一轮竞争的门票。","market":"us","thumbnail":"https://img7.gelonghui.com/column/10.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/10.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6975430","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1593","BK1600","BK1515","00460","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673406077","title":"四环医药(00460.HK)战略投资汉腾生物，完善再生医美全产业链布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2673406077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673406077?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:54","pubTimestamp":1791464080,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141924092","title":"四环医药（00460）子公司完成对汉腾生物战略投资 加速再生医美全产业链布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1141924092","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141924092?lang=zh_cn&edition=full","pubTime":"2026-10-08 20:52","pubTimestamp":1791463928,"startTime":"0","endTime":"0","summary":"2026年10月8日，四环医药控股集团有限公司发布自愿性公告称，其旗下渼颜空间生物科技（吉林）有限公司已完成对广州汉腾生物科技有限公司的战略股权投资，并计划围绕汉腾生物的全长三螺旋重组人III型胶原蛋白原料开展联合商业化合作。1) 获取完整三螺旋结构的全长重组人III型胶原蛋白稳定供应，突破行业片段化胶原及动物源胶原的原料瓶颈；","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","SG9999002463.SGD","09926","IBBQ","ZLAB","LNGR","BK1515","BK1161","IE00BPRC5H50.USD","LU1242518931.SGD","LU0029874905.USD","BK1574","BK1141","LU0320764599.SGD","LU0708995153.HKD","IE00BZ08YT58.USD","02228","BK4139","LU0359201612.USD","LU2476274308.USD","LU0052750758.USD","09688","01672","LU0320764243.SGD","01952","LU0211977185.USD","LU0348735423.USD","LU0029874061.USD","00460","01477","159992","01548","BK4588","LU0348784397.USD","LU0417516902.SGD","MEDX","HK0000306701.USD","LU0348827113.USD","01177","02269","KURE","BK1521","LU0516422366.SGD","LU0516423091.SGD","01530","LU0348766576.USD","LU0140636845.USD","LU0823426308.USD","BK1191","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705076","title":"四环医药(00460)：水光针(商品名：冻妍)新增规格获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705076","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673705076?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:04","pubTimestamp":1791191081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布公告，本集团旗下渼颜空间生物科技(吉林)有限公司自主研发的注射用透明质酸钠复合溶液五个新增规格已正式获得中国国家药品监督管理局批准上市。本次新增规格获批为该产品上市后的重要进展，进一步夯实本集团在轻医美水光赛道的产品布局与竞争力。目前，渼颜空间在全球落成三个生产基地，具有完善的品质管理体系，并对产品的全生命周期实施有效风险管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1515","BK1600","00460","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107235859","title":"四环医药（00460）水光针“凍妍”再添五款新规格获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1107235859","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107235859?lang=zh_cn&edition=full","pubTime":"2026-10-05 17:02","pubTimestamp":1791190943,"startTime":"0","endTime":"0","summary":"2026年10月5日，四环医药公告称，旗下渼颜空间生物科技（吉林）有限公司自主研发的注射用透明质酸钠复合溶液新增0.75mL╱支、1.25mL╱支、1.75mL╱支、2.25mL╱支、2.75mL╱支共五个规格，已获得中国国家药品监督管理局批准上市。至此，“凍妍”已形成涵盖0.5mL至3.0mL区间的十二项剂量谱系。公司指出，水光针作为轻医美核心品类，具有较高复购属性。四环医药表示，本次获批的梯度化规格可为同类产品的研发与迭代提供参考，有助于促进行业规范化、精细化发展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152330279","title":"四环医药更新2026年9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1152330279","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152330279?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:15","pubTimestamp":1790928948,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司于2026年10月2日发布截至2026年9月30日的证券变动月报表。公告显示，公司本月未发生新增股份发行或股份购回等交易活动，股本结构保持稳定。截至2026年9月30日，公司已发行股份及库存股份总数维持在9,329,999,206股，较上月无变化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170708","title":"【券商聚焦】广发证券首予四环医药（00460）买入评级 指医美与创新药进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170708","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669170708?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:04","pubTimestamp":1790143494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 广发证券发布研报指，四环医药 早期起家于心脑血管等仿制药业务，在医药集采期主动求变，积极向医美与创新药业务转型，2025年利润扭亏为盈，26H1归母净利达2.2亿元，进入业绩兑现阶段。渠道端，至26H1医美渠道覆盖终端机构超9000家，于行业承压下实现医美收入6.9亿元，同增18.5%，税前利润3.4亿元，同增10.9%。公司加速剥离非核心资产，创新药减亏与医美利润兑现进一步改善报表质量。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","IBBQ","06978","00460","KCE","MEDX","01776","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","BK1600","BK1515","HK0000165453.HKD","BK1587","01530","03600","BK1583","BK1100","06699","00460","00719","BK1161","06826","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169352351","title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169352351","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169352351?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:57","pubTimestamp":1789549054,"startTime":"0","endTime":"0","summary":"四环医药发布2026年中期业绩。报告期内，公司实现营收11.61亿元，同比上升1.3%。本期毛利为6.82亿元，上年同期为7.57亿元，毛利率为58.7%。经营利润达3.13亿元，上年同期约2.64亿元，同比增长18.6%。经营活动现金流为-0.92亿元，上一年同期为-0.95亿元。分销开支2.17亿元，同比下降6.1%，占营收比例约18.71%；行政开支2.07亿元，同比下降2.2%；研发投入1.06亿元，同比下降30.9%，占营收比例约9.09%。公司医疗美容业务收入6.93亿元，同比增长18.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664386607","title":"港股异动 | 四环医药(00460)午前涨近4% 轩竹生物与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386607?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","00460","BK1600","VXUS","KCAI","BK4588","02575","BK1191","BK1515","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162680804","title":"四环医药(00460)子公司轩竹生物携手Innobic　独家推进吡洛西利片进入泰国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1162680804","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162680804?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:21","pubTimestamp":1788427316,"startTime":"0","endTime":"0","summary":"2026年9月3日，四环医药控股集团有限公司发布自愿公告称，其非全资附属公司轩竹生物科技股份有限公司已与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd签署有关吡洛西利片的三方商业协议，协议有效期至2036年6月30日。根据协议，轩竹生物向Innobic（亚洲）及早安国际授予吡洛西利片在泰国市场的独家商业化权利，涵盖进口、推广、营销、要约销售、销售及经销等环节。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385197","title":"四环医药(00460.HK)授出合共1.16亿份股份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664385197?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:01","pubTimestamp":1788267673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1191","BK1515","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.1034},{"period":"1month","weight":0.1189},{"period":"3month","weight":-0.116},{"period":"6month","weight":-0.3361},{"period":"1year","weight":-0.4257},{"period":"ytd","weight":-0.3416}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家主要从事研发、制造及销售医药产品和医美产品的投资控股公司。该公司通过三个分部运营其业务。医美产品分部包括填充类、塑形类、支撑类、补充类、光电设备类、体雕类、皮肤管理类及其他以及提供轻医美综合解决方案。创新药及其他药品分部从事研发及商业化糖尿病、乳腺癌、消化、肿瘤及非酒精性脂肪型肝炎等疾病领域的创新药。仿制药分部从事包括克林澳等仿制药的生产和销售。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119713},{"month":2,"riseRate":0.5,"avgChangeRate":0.000651},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.032043},{"month":4,"riseRate":0.533333,"avgChangeRate":0.038601},{"month":5,"riseRate":0.4,"avgChangeRate":0.003084},{"month":6,"riseRate":0.533333,"avgChangeRate":-0.005353},{"month":7,"riseRate":0.6,"avgChangeRate":0.012776},{"month":8,"riseRate":0.466667,"avgChangeRate":-0.024743},{"month":9,"riseRate":0.2,"avgChangeRate":-0.043907},{"month":10,"riseRate":0.533333,"avgChangeRate":0.027292},{"month":11,"riseRate":0.5,"avgChangeRate":0.014281},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017751}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}